pseudoephedrine (Sudafed, Afrin, Drixoral, SudoGest)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Sudafed. Restricted substance* (see alternatives to pseudoephedrine)

Indications

* avoid for treatment of allergic rhinitis[8]

Contraindications

use with caution in patients with:

pregnancy category = c

safety in lactation = -

Dosage

  • 60 mg PO every 4-6 hours.
  • 30 mg/dose if 6-13 yo.
  • 15 mg/dose if 2-5 yo.

Tabs: 30 & 60 mg.

Elixir: 30 mg/5 mL. Timed-release: Afrin, Drixoral. 120 mg PO BID. Tabs: 120 mg. Infant drops: (PediaCare Infant's decongestant) 7 drops/kg PO every 4-6 hours up to 4 doses/day if > 1 yo. 3 drops/kg if 3-12 months.

Pharmacokinetics

elimination via liver

Adverse effects

Drug interactions

Laboratory

Mechanism of action

* Because of the potential for chemical conversion to methamphetamine, pseudoephedrine & ephedrine are restricted substances. As of Sept 30, 2006, pseudoephedrine & ephedrine will be behind the counter. Only 3.6 g/day & 9 g/month will be dispensed. This works out to be 120 tablets of pseudoephedrine 30 mg per day, or 300 tabs/month.[5]

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. 3.0 3.1 Prescriber's Letter 10(10):60 2003
  4. 4.0 4.1 4.2 Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005 Aug 8-22;165(15):1686-94. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16087815
    Coates ML, Rembold CM, Farr BM. Does pseudoephedrine increase blood pressure in patients with controlled hypertension? J Fam Pract. 1995 Jan;40(1):22-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7807033
  5. 5.0 5.1 Prescriber's Letter 13(4): 2006 New Rules for the Sale of Pseudoephedrine and other Methamphetamine Precursors Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220413&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 6.2 Deprecated Reference
  7. 7.0 7.1 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  8. 8.0 8.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/

Database